Key Highlights
- Shares closed at $4.59 at last closing, down 1.92%, in penny-stock territory.
- The company completed a one-for-twenty-one Reverse Stock Split and held cash of only about $5 million as of mid-2026, implying a runway of roughly a few months.
- It has conducted repeated warrant-inducement financings that add dilution and a Warrant overhang.
- Autonomix Medical is a pre-revenue, clinical-stage medical-device company developing catheter-based sensing-and-ablation technology targeting pain from pancreatic and other visceral cancers.
Penny stock Autonomix Medical (NASDAQ:AMIX) is a pre-revenue, clinical-stage medical-device micro-cap developing a catheter-based sensing-and-ablation technology that aims to detect and treat peripheral nerve signals, with a lead program targeting pain from pancreatic and other visceral cancers. Shares closed at $4.59 at last closing, down 1.92%.
As a company with no product revenue, its results depend on the progress of its clinical programs, its cash runway, and its ability to raise capital, so it is highly speculative and dependent on financing, with its technology not yet validated in humans.
Latest Developments
As of mid-2026, Autonomix had completed a one-for-twenty-one reverse stock split, held cash of only about $5 million against a burn implying a runway of roughly a few months, and had conducted repeated warrant-inducement financings that add dilution and a warrant overhang, while reporting some positive preclinical and animal-study data supporting a planned regulatory submission. Investors should verify the cash position and runway, financing and dilution, and clinical status directly from SEC filings, recognizing that the company is pre-revenue with a short runway and faces going-concern and dilution risk.
Financial and Business Position
As a pre-revenue clinical-stage micro-cap, Autonomix's financial position is defined by its minimal cash, its ongoing losses and burn, and its short runway, so its future depends almost entirely on raising Capital without crushing its tiny float. Investors should focus on the cash position and runway, financing and dilution, and clinical status.
Stock-Market Context
AMIX shares closed at $4.59 at last closing, down 1.92%, keeping the stock in penny territory. The stock is a distressed, speculative micro-cap whose shares are extremely volatile and sensitive to financing, dilution, and clinical news, and the selloff has been driven by dilution and runway fears more than any single event.
What Investors Should Watch
Watch the cash position and runway, the net loss and burn, financing and dilution, and clinical and regulatory status. A financing that avoids crushing the float, combined with clean clinical progress, would be needed for any recovery, while continued dilution or a funding shortfall would confirm the downside risk.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...